Sign In
Buy HOOK
$1.15
+0 (+0%)
At Close: Jun 03, 2026
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
07:01am, Thursday, 25'th Apr 2024
NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprie
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
07:01am, Wednesday, 24'th Apr 2024
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav
Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts
02:20pm, Monday, 22'nd Apr 2024
Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design. A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 16'th Apr 2024
NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
07:01am, Wednesday, 10'th Apr 2024
NEW YORK and VIENNA, Austria, April 10, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprie
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
09:16am, Friday, 22'nd Mar 2024
HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
07:01am, Friday, 22'nd Mar 2024
NEW YORK and VIENNA, Austria, March 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
07:01am, Wednesday, 06'th Mar 2024
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav
All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy
01:01pm, Friday, 02'nd Feb 2024
HOOKIPA Pharma Inc. (HOOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for February 2nd
11:01am, Friday, 02'nd Feb 2024
BK, HCA and HOOK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 2, 2023.
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
08:01am, Monday, 29'th Jan 2024
NEW YORK and VIENNA, Austria, Jan. 29, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
07:01am, Tuesday, 16'th Jan 2024
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi
HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment
10:30am, Friday, 22'nd Dec 2023
New York, December 22, 2023 – Gilead Sciences (Nasdaq: GILD) has purchased 15 million shares of immunotherapeutics company, HOOKIPA Pharma's (Nasdaq: HOOK), common stock for approximately $21
Why Is Hookipa Pharma (HOOK) Stock Up 81% Today?
09:15am, Thursday, 21'st Dec 2023
Hookipa Pharma (NASDAQ: HOOK ) stock is on the rise Thursday as investors react to news of a share purchase agreement with Gilead Sciences (NASDAQ: GILD ). According to a filing with the Securities a
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
07:01am, Thursday, 21'st Dec 2023
NEW YORK and VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi
